

UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL
FACULDADE DE FARMÁCIA
TRABALHO DE CONCLUSÃO DE CURSO

Experimental evidence that *in vivo* intracerebral administration of L-2-hydroxyglutaric acid to neonatal rats provokes disruption of redox status and histopathological abnormalities in the brain

Rafael Teixeira Ribeiro

Porto Alegre, Dezembro de 2017.

UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL
FACULDADE DE FARMÁCIA
TRABALHO DE CONCLUSÃO DE CURSO

Experimental evidence that *in vivo* intracerebral administration of L-2-hydroxyglutaric acid to neonatal rats provokes disruption of redox status and histopathological abnormalities in the brain

Rafael Teixeira Ribeiro

Prof. Dr. Moacir Wajner
Orientador

Porto Alegre, Dezembro de 2017.

Este trabalho foi elaborado segundo as normas da revista “Molecular Neurobiology”, conforme Anexo II, na qualidade de “Artigo Original”

Experimental evidence that *in vivo* intracerebral administration of L-2-hydroxyglutaric acid to neonatal rats provokes disruption of redox status and histopathological abnormalities in the brain

Rafael Teixeira Ribeiro³, Ângela Zanatta¹, Alexandre Umpierrez Amaral^{1,2}, Guilhian Leipnitz^{1,3}, Bianca Seminotti¹, Moacir Wajner^{1,3,4}

1 - Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

2 - Departamento de Ciências Biológicas, Universidade Regional Integrada do Alto Uruguai e das Missões, Erechim, RS, Brazil

3 - Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS CEP 90035-003, Brazil

4 - Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Acknowledgements

This work was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico #404883/2013-3, Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul #2266-2551/14-2, Pró-Reitoria de Pesquisa/Universidade Federal do Rio Grande do Sul #PIBIC 27613, FIPE/HCPA and Financiadora de Estudos e Projetos/Rede Instituto Brasileiro de Neurociência # 01.06.0842-00.

***Corresponding author:** Moacir Wajner, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal de Rio Grande do Sul, Rua Ramiro Barcelos, 2600 – Anexo, CEP 90035-003, Porto Alegre, RS, Brazil.

Abstract

Tissue accumulation of L-2-hydroxyglutaric acid (L-2-HG) is the biochemical hallmark of L-2-hydroxyglutaric aciduria (L-2-HGA), a rare neurometabolic inherited disease characterized by neurological symptoms and brain white matter abnormalities whose pathogenesis is not yet well established. L-2-HG was intracerebrally administered to rat pups at postnatal day 1 (P1) to induce a rise of L-2-HG levels in the central nervous system (CNS). Thereafter, we investigated whether L-2-HG *in vivo* administration could disturb redox homeostasis and induce brain histopathological alterations in cerebral cortex and striatum of neonatal rats. L-2-HG markedly induced the generation of reactive oxygen species (increase of 2',7'-dichlorofluorescein-DCFH- oxidation), lipid peroxidation (increase of malondialdehyde concentrations) and protein oxidation (increase of carbonyl formation and decrease of sulfhydryl content), besides decreasing the antioxidant defenses (reduced glutathione-GSH) and sulfhydryl content in cerebral cortex. Alterations of the activities of various antioxidant enzymes were also observed in cerebral cortex and striatum following L-2-HG administration. Furthermore, L-2-HG-induced lipid peroxidation and GSH decrease in cerebral cortex were prevented by the antioxidant melatonin and by the classical antagonist of NMDA glutamate receptor MK-801, suggesting the involvement of reactive species and of overstimulation of NMDA receptor in these effects. Finally, L-2-HG provoked vacuolation and edema particularly in the cerebral cortex with less intense alterations in the striatum that were possibly associated with the unbalanced redox homeostasis caused by this metabolite. Taken together, it is presumed that these pathomechanisms may underlie the neurological symptoms and brain abnormalities observed in the affected patients.

Keywords: L-2-hydroxyglutaric aciduria; L-2-hydroxyglutaric acid; redox homeostasis; cerebral cortex; striatum; histopathology.

Introduction

L-2-Hydroxyglutaric aciduria (L-2-HGA; MIM#236792) is a rare autosomal recessive inborn error of metabolism caused by mutations in the *L-2-hydroxyglutarate dehydrogenase* gene (*L2HGDH*), resulting in highly elevated levels of L-2-hydroxyglutaric acid (L-2-HG) in tissues and biological fluids (urine, plasma, and cerebro-spinal fluid). The *L2HGDH* gene is expressed in multiple tissues, with the strongest expression in the brain [1]. To date, there are over three hundred documented cases of this disease in the medical literature [2-7]. The main neurological manifestations include progressive mental retardation, variable motor impairment and cerebellar ataxia. Most patients also present macrocephaly, pyramidal and extrapyramidal signs, dystonia and a typical MRI profile with striking subcortical leucoencephalopathy and basal ganglia abnormalities [5,8]. Characteristic brain MRI findings in L-2-HGA comprise alterations in the subcortical cerebral white matter, dentate nucleus, globus pallidus, putamen and caudate nucleus [5]. As the disease progresses, alterations of white matter and basal ganglia signal intensities become more diffuse, followed by cerebral white matter atrophy [3]. A strong correlation between the clinical disability and the extent of pathologic changes on MRI has been reported, but this is still under debate [5].

The mechanisms of the neurological symptoms presented by L-2-HGA patients are still poorly understood. However, increased concentrations of L-2-HG were associated with the appearance of neurological symptoms, indicating that this organic acid may be potentially neurotoxic in this disorder [9-12]. In this context, it was verified that L-2-HG inhibits creatine kinase activity in rat cerebellum homogenates [13], induces oxidative stress [14] and increases glutamate uptake in synaptosomes and synaptic vesicles [15]. Furthermore, it was demonstrated that intracerebral administration of L-2-HG to rats induces oxidative stress by decreasing the antioxidant defenses and raising reactive oxygen species in striatum and cerebellum of rats, besides causing marked brain histopathological alterations [16].

Considering that the brain is highly susceptible to free radical attack due to its low antioxidant defenses and high oxygen consumption potentially leading to a proportionally high mitochondrial production of reactive species [17], in the present study we investigated the effects of intracerebral administration of L-2-HG on a large spectrum of redox homeostasis parameters in cerebral cortex and striatum of neonatal rats. Lipid oxidative damage (malondialdehyde levels), protein oxidation (carbonyl formation and sulfhydryl content), reactive oxygen species (DCFH oxidation), and the non-enzymatic (GSH levels) and enzymatic antioxidant defenses (glutathione peroxidase, glutathione reductase, glutathione S-transferase, glucose-6-phosphate dehydrogenase, catalase and superoxide dismutase) were evaluated. We also investigated whether L-2-HG could provoke-histopathological changes in the brain of these animals.

Material and Methods

Animals

Neonatal Wistar rats obtained from the Central Animal House of the Department of Biochemistry, ICBS, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil, were used. Six whole litters of 12 animals each were used for each experimental *in vivo* condition. The animals had free access to water and 20% (w/w) protein commercial chow (SUPRA, Porto Alegre, RS, Brazil) and were maintained on a 12:12-h light/dark cycle in an air-conditioned constant temperature ($22\text{ }^{\circ}\text{C} \pm 1\text{ }^{\circ}\text{C}$) colony room. The experimental protocol was approved by the Ethics Committee for animal research of the Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, and followed the “Guide for the Care and Use of Laboratory Animals” (NIH publication 85-23, revised 2011). All efforts were made to minimize the number of animals used and their suffering.

Reagents

All chemicals were purchased from Sigma Chemical Co., St. Louis, MO, USA. L-2-HG was dissolved in phosphate-buffered saline (PBS) on the day of the experiments, and the pH was adjusted to 7.4.

L-2-HG administration and drug treatment

Seventy-two neonatal pups were used in the experiments. Each littermate was injected intracerebrally into the Cisterna magna, as previously described [18,19], between 12 and 48 hours after birth (P1) with L-2-HG (0.75 $\mu\text{mol/g}$, pH 7.4) or vehicle (phosphate buffered saline (PBS), 0.01 M, pH 7.4). After injection, animals were allowed to recover during 15–30 min and returned to their mother. In some experiments, the antioxidant melatonin (MEL; 20 mg/kg body weight) [20] or the classical NMDA receptor antagonist MK-801 (0.25 mg/kg body weight) [16] was administered intraperitoneally 60 min before L-2-HG administration.

Sample Preparation

Six hours after L-2-HG injection, animals were euthanized by decapitation, and the brain was immediately removed and kept on an ice Petri plate. The olfactory bulb, pons, and medulla were discarded and the cerebral cortex and striatum were dissected, weighed, and kept chilled until homogenization. These structures were homogenized (1:10 w/v) in 20 mM sodium phosphate, pH 7.4, containing 140 mM chloride potassium (1:10 w/v), centrifuged at 750 g for 10 min and the supernatants used for the assays.

Malondialdehyde Levels

MDA concentrations were measured according to the method described by Yagi [21] with some modifications. Briefly, one hundred microliters of cerebral cortex or striatum supernatants containing 0.3 mg of protein were treated with 200 μ L of 10 % trichloroacetic acid and 300 μ L of 0.67 % thiobarbituric acid in 7.1 % sodium sulfate and incubated for 1 h in a boiling water bath. The tubes containing the mixture were allowed to cool on running tap water for 5 min. The resulting pink-stained complex was extracted with 400 μ L of butanol. Fluorescence of the organic phase was read at 515 and 553 nm as excitation and emission wavelengths, respectively. A calibration curve was performed using 1,1,3,3-tetramethoxypropane and subjected to the same treatment as supernatants. MDA levels were calculated as nmol MDA / mg protein.

Sulfhydryl Group Content

This assay was performed according to Aksenov and Markesbery [22]. It is based on the reduction of 5,5'-dithio-bis(2-nitrobenzoic acid) DTNB by thiol groups, generating a yellow-stained compound TNB whose absorption is measured spectrophotometrically at 412 nm. Thirty microliters of 0.1 mM DTNB was added to 120 μ L of cerebral cortex or striatum supernatants containing 0.36mg of protein. This was followed by 30-min incubation at room temperature in a dark room. Absorption was measured at 412 nm. Results were calculated as nmol TNB / mg protein.

Protein carbonyl formation

Protein carbonyl formation was measured according to the method of Reznick and Packer [23]. The assay is based on the reaction of the carbonyl groups with 2,4-dinitrophenylhydrazine (DNPH) generating a corresponding dinitrophenyl hydrazone, whose absorbance is read in spectrophotometer at 370 nm. Briefly, 200 μ L of cerebral cortex or striatum supernatants were treated with 400 μ L of 10 mM DNPH dissolved in 2.5 M HCl or with 2.5 M HCl (blank) and left in the dark for 1 h. Samples were then precipitated with 600 μ L of 20 % TCA and centrifuged for 5 min at 9,000 g. The pellet was washed with 1 mL of ethanol:ethyl acetate (1:1, v/v) and suspended in 550 μ L of 6 M guanidine prepared in 2.5 N HCl. The difference between the absorbance of the samples treated with DNPH and with HCl (blank) was used to calculate the carbonyl content. The results were calculated as nmol carbonyl groups / mg of protein, using the extinction coefficient of $22,000 \times 10^6$ nmol / mL for aliphatic hydrazones.

Reduced glutathione concentrations

This parameter was measured according to Browne and Armstrong [24] with some modifications. One hundred and eighty-five microliters of 100 mM sodium phosphate buffer, pH 8.0, containing 5 mM EDTA, and 15 μ L of o-phthalaldehyde (1 mg/mL) were added to 30 μ L of sample (0.3–0.5 mg of protein) previously deproteinized with metaphosphoric acid. This mixture was incubated at room temperature in a dark room for 15 min. Fluorescence was measured using excitation and emission wavelengths of 350 and 420 nm, respectively. Calibration curve was prepared with standard GSH (0.001–1 mM), and the concentrations were calculated as nmol GSH / mg protein.

2',7'-Dichlorofluorescein oxidation

DCFH oxidation was determined according to the method of LeBel [25] with slight modifications. Homogenates (0.04–0.07 mg protein) were incubated with 2',7'-dichlorofluorescein diacetate (DCF-DA) (5 μ M) during 1 h at 37°C. DCF-DA is permeable to the cell membrane and is deacetylated by esterases to DCFH in the intracellular medium. DCFH is then converted by reactive species into the highly fluorescent product dichlorofluorescein (DCF). DCF fluorescence was measured using wavelengths of 480 nm (excitation) and 535 nm (emission). The calibration curve was performed with standard DCF (0.01–0.75 μ M). The production of reactive species was calculated as μ mol DCF / mg protein.

Nitrate and nitrite content

Reactive nitrogen species (RNS) formation was evaluated by measuring nitrate and nitrite content according to Navarro-Gonzalvez and collaborators [26], with some modifications. One hundred and fifty microliters of supernatants (containing approximately 1.2 mg of protein) was deproteinized by adding 125 mL of 75 mM ZnSO₄ solution, followed by centrifugation at 9,000 g for 2min at 25°C. The supernatant obtained was neutralized with 55mM NaOH solution and diluted in 5 vol of glycine buffer solution, pH 9.7. Copper-coated cadmium granules (600–1,000 mg) were added to the supernatants to convert all nitrates into nitrite in the biological samples. Aliquots of 200 μ L were then treated with 200 μ L of Griess reagent (2% sulfanilamide in 5% HCl and 0.1% N-1-(naphthyl)ethylenediamine in H₂O) and incubated at room temperature for 10 min. The absorbance was read at 505nm. A calibration curve was prepared with NaNO₂ at concentrations ranging from 1 to 125 mM. The final results were expressed in μ mol nitrate and nitrite / mg protein.

Glutathione peroxidase (GPx) activity

GPx activity was measured according to Wendel [27] using tert-butylhydroperoxide as substrate. The enzyme activity was determined by monitoring the NADPH disappearance at 340 nm in a medium containing 600 μ L of buffer (100 mM potassium phosphate containing 1 mM EDTA, pH 7.0), 10 μ L of 40 mM sodium azide, 15 μ L of 100 mM GSH, 15 μ L of 10 U/mL glutathione reductase, 10 μ L of 10 mM NADPH, and 10 μ L of sample (3 μ g of protein). One GPx unit (U) is defined as 1 μ mol of NADPH consumed per minute. The specific activity was calculated as U / mg protein.

Glutathione reductase (GR) activity

GR activity was measured as previously described by Carlberg and Mannervik [28]. The enzyme activity was determined by monitoring NADPH consumption at 340 nm in a medium with 200 mM sodium phosphate buffer, pH 7.5, containing 6.3 mM ethylenediaminetetraacetic acid, 1 mM GSSG, 0.1 mM NADPH, and approximately 3 µg of protein. One GR unit (U) is defined as 1 µmol of GSSG reduced per minute. The specific activity was calculated as U / mg protein.

Glutathione-S-transferase (GST) activity

GST activity was measured according to Mannervik and Guthenberg [29], with slight modifications, by monitoring the rate of formation of dinitrophenyl-S-glutathione at 340 nm in a medium containing 50 mM potassium phosphate, pH 6.5, 1 mM GSH, 1 mM 1-chloro-2,4-dinitrobenzene (CDNB) as substrate, and tissue supernatants (approximately 0.045 mg of protein). The results were calculated as U / mg protein.

Glucose-6-phosphate dehydrogenase (G6PDH) activity

G6PDH activity was measured according to Leong and Clark [30], following NADPH formation at 25°C at 340 nm. The reaction medium contained tissue supernatants (approximately 45 µg of protein), 100 mM Tris-HCl buffer, pH 7.5, 1.0 mM MgCl₂, 0.05 mM NADP⁺ and 0.1 mM glucose-6-phosphate. The results were calculated as U / mg protein.

Catalase (CAT) activity

CAT activity was assayed according to Aebi [31] by measuring the absorbance decrease at 240 nm in a reaction medium containing 20 mM H₂O₂, 0.1 % Triton X-100, 10 mM potassium phosphate buffer, pH 7.0, and approximately 1 µg of protein. One unit (U) of the enzyme is defined as 1 µmol of H₂O₂ consumed per minute. The specific activity was calculated as U / mg protein.

Superoxide dismutase (SOD) activity

SOD activity was assayed according to Marklund [32] and is based on the capacity of pyrogallol to autoxidize, a process highly dependent on superoxide anion, which is the substrate for SOD. The inhibition of the autoxidation of pyrogallol occurs in the presence of SOD and, therefore, is proportional to the activity of the SOD present in homogenates. The reaction medium contained 50 mM Tris buffer/1 mM ethylenediaminetetraacetic acid, pH 8.2, 80 U/mL CAT, 0.38 mM pyrogallol, and approximately 1 µg of protein, and the absorbance was read at 420 nm. A calibration curve was performed with purified SOD as standard, in order to calculate the activity of SOD present in the samples. The specific activity was calculated as U / mg protein.

Histological analysis

We performed histological analysis in the brain with hematoxylin and eosin staining. Four rats of each group (PBS or L-2-HG-injected animals) were euthanized 24 hours after PBS or L-2-HG (0.75 $\mu\text{mol/g}$) administration. The whole brain was removed and postfixed in 10% formaldehyde-buffered solution, pH 7.0, for 48 hours at room temperature and processed for paraffin-embedded sectioning. Three-micrometer-thick brain slices were obtained with a microtome (MICROM HM 360). Brain sections were stained in hematoxylin solution for 5 min and then washed in running tap water. The sections were then placed in eosin solution for 3 min, dehydrated with 100 % ethanol and cleared with xylene for 2 min. Image analysis (magnification of 100x and 400x) was performed using the Q Capture Pro Software (Olympus).

Protein Determination

Protein content was measured by the method of Lowry [33], using bovine serum albumin as a standard.

Statistical Analysis

Results are presented as mean \pm standard deviation. Assays were performed in triplicate, and the mean was used for statistical calculations. Data were analyzed using the Student's *t* test for unpaired samples or one-way analysis of variance (ANOVA) followed by the post-hoc Duncan multiple range test when F was significant. Only significant values are shown in the text. Differences between groups were considered significant at $P < 0.05$. All analyses were carried out using the GraphPad Prism 5 software.

Results

In vivo L-2-HG administration provokes lipid and protein oxidative damage in neonatal rat cerebral cortex

We initially observed that L-2-HG markedly enhanced (75%) MDA levels in cerebral cortex of neonatal rats 6 h after its administration [$t_{(7)} = 4.321$; $P < 0.01$] (Figure 1A). Since MDA is an end product of membrane polyunsaturated fatty acid peroxidation, these data indicate that L-2-HG causes lipid oxidative damage. L-2-HG also increased carbonyl formation (11%) [$t_{(5)} = 3.317$; $P < 0.05$] (Figure 1B), and decreased sulfhydryl content (34%) [$t_{(5)} = 5.020$; $P < 0.01$] (Figure 1C). Since carbonyl group generation is currently used as a marker of free radical-mediated protein oxidation and two thirds of total cellular sulfhydryl groups are protein bound [34,35], our results indicate that L-2-HG induces protein oxidative damage in cerebral cortex.

L-2-HG decreases the antioxidant defenses in rat cerebral cortex

Next, we observed that L-2-HG decreased the concentrations of GSH (25%) [$t_{(8)} = 5.655$; $P < 0.001$] (Figure 2), implying an impairment of brain antioxidant defenses by this organic acid.

L-2-HG induces reactive oxygen species (ROS) generation in rat cerebral cortex

We also investigated whether L-2-HG could induce reactive species generation that could possibly lead to protein and lipid oxidative damage as well as to reduction of antioxidant defenses. Thus, we tested the effects of L-2-HG on ROS production, determined by DCFH oxidation in cerebral cortex, and on RNS generation measured by nitrate and nitrite concentrations. L-2-HG significantly increased DCFH oxidation (up to 25 %) [$t_{(5)} = 2.914$; $P < 0.05$] (Figure 3A) but, in contrast, did not change the levels of nitrates and nitrites (Figure 3B).

L-2-HG-induced lipid peroxidation and decreased antioxidant defenses are prevented by melatonin (MEL) and MK-801 in neonatal rat cerebral cortex

Since L-2-HG induced ROS formation, we tested whether the reactive species scavenger MEL could prevent lipid oxidation and the decrease of the antioxidant defenses caused by this metabolite. We observed that MEL totally prevented MDA increase [$t_{(4)} = 2.788$; $P < 0.05$] (Figure 4A) and GSH decrease [$t_{(6)} = 7.476$; $P < 0.001$] (Figure 4B) caused by L-2-HG. These data support the involvement of ROS in these effects and may offer a new perspective of treatment with antioxidants. Furthermore, the effects on MDA levels [$t_{(5)} = 3.995$; $P < 0.05$] and GSH concentrations [$t_{(6)} = 4.208$; $P < 0.01$] were similarly abolished by the NMDA receptor antagonist MK-801 (Figures 4A and 4B), indicating overactivation of NMDA receptors by L-2-HG.

L-2-HG modulates the activities of antioxidant enzymes in neonatal rat cerebral cortex

The effects of L-2-HG intracerebroventricular administration on the enzymatic antioxidant defenses were further studied. We verified that L-2-HG reduced G6PDH activity (14%) [$t_{(6)} = 2.775$; $P < 0.05$] (Figure 5A), and increased GPx (18%) [$t_{(5)} = 4.326$; $P < 0.05$] (Figure 5B), GR (20%) [$t_{(6)} = 4.326$; $P < 0.01$] (Figure 5C) and GST (39%) [$t_{(6)} = 3.914$; $P < 0.01$] (Figure 5D) activities. In contrast, CAT (Figure 5E) and SOD (Figure 5F) activities were not altered by the metabolite.

L-2-HG mildly disrupts redox homeostasis in neonatal rat cerebral striatum

We also observed that L-2-HG administration decreased sulfhydryl content (50%) [$t_{(4)} = 10.13$; $P < 0.001$] (Figure 6A), but did not alter MDA levels, GSH concentrations and ROS formation (DCFH oxidation) in rat striatum. It was also verified that L-2-HG modulated the enzymatic antioxidant defenses by increasing GPx (35%) [$t_{(5)} = 3.255$; $P < 0.05$] (Figure 6B), G6PDH (20%) [$t_{(5)} = 3.354$; $P < 0.05$] (Figure 6C) and SOD (22%) [$t_{(7)} = 4.633$; $P < 0.01$] (Figure 6D) activities, with no changes in the activities of GR and GST.

L-2-HG provokes extensive vacuolation in neonatal rat cerebral cortex

The effect of L-2-HG intracerebroventricular administration on the brain histological integrity was then studied by HE staining. We observed that L-2-HG administration provoked intense edema and vacuolation in the cerebral cortex (Figure 7) with less effects in the striatum (Figure 8).

Discussion

L-2-HGA is clinically characterized by predominant neurological findings, such as psychomotor delay/mental deficiency, extrapyramidal and pyramidal symptoms, macrocephaly, seizures demyelination of white matter, cerebral and cerebellar atrophy, seizures, leukoencephalopathy, and other neurologic manifestations [4-6]. In some patients, this disorder leads to the formation of brain tumors [36-38], whose etiology is still poorly known. Accumulation of L-2-HG in tissues, predominantly in the brain, is the biochemical hallmark of this disease, and this may be because the mutated gene is highly expressed in the brain [1]. Although the disorder is predominantly neurologic, its pathogenesis is not yet established. However, it was suggested that the pathologic phenotypes of affected patients result from the toxic effects of L-2-HG on central nervous system [39]. In this context, the structural resemblance of L-2-HG to L-glutamate and α -ketoglutarate, two major metabolites of the glutamatergic system, makes it likely that the pathophysiology of the disease may involve alterations of this system or pathways of α -ketoglutarate metabolism. Furthermore, previous *in vitro* and *in vivo* studies have shown disruption of redox homeostasis provoked by L-2-HG, as well as alterations of the glutamatergic system in developing rats and affected patients with L-2-HGA [14-16,40].

It is of note that nothing has been reported on the brain toxicity of L-2-HG in neonatal brain. Therefore, in the present study we investigated whether L-2-HG *in vivo* administration could disturb redox status and induce histopathological alterations in cerebral cortex and striatum of neonatal rats. It is emphasized that these cerebral structures are mainly affected in L-2-HGA, as observed in cerebral imaging by leukoencephalopathy/spongiosis of white matter, subcortical abnormalities and caudate and putamen alterations [41,42].

We verified that L-2-HG administration markedly increased MDA levels in cerebral cortex, corroborating the *in vitro* and *in vivo* findings previously reported and showing that L-2-HG increases the levels of thiobarbituric acid-reactive substances in brain of 30-day-old rats [14,16]. Since MDA is an end product of membrane fatty acid peroxidation, these data indicate that L-2-HG induces lipid oxidative damage. L-2-HG also markedly increased carbonyl groups and decreased sulfhydryl content. Since carbonyl groups are formed by oxidation of amino acid side chain protein residues (Pro, Arg, Lys, and Thr) and two thirds of sulfhydryl groups in cells are protein bound [34,35], it is assumed that L-2-HG induces protein oxidative damage in the brain.

L-2HG also caused a significant decrease of GSH concentrations in cerebral cortex that could be tentatively attributed to its oxidation by increased reactive species generation. Since GSH represents the major naturally-occurring tissue antioxidant and plays a key role in maintaining the intracellular redox

state protecting crucial cellular sulfhydryl groups [17], our present findings suggest that L-2-HG impairs the tissue non enzymatic antioxidant defenses.

DCFH oxidation was also increased by L-2-HG, but, in contrast, this organic acid did not change nitrate and nitrite content, reflecting induction of ROS generation. It could be also hypothesized that the increase of ROS formation could lead secondarily to increased lipid and protein oxidation and decreased GSH concentrations. On the other hand, since GSH is considered an important defense against lipid oxidative damage by scavenging reactive species responsible for the initiation of this process, it is feasible that the decrease of this antioxidant could make lipids and proteins more vulnerable to the oxidative damage caused by L-2-HG through ROS formation.

Moreover, the free radical scavenger melatonin prevented L-2-HG-induced reduction of GSH levels and increase of MDA concentrations, strongly indicating that disturbance of cellular redox status was secondary to reactive species production provoked by L-2-HG. It is likely that hydroxyl and peroxy radicals were involved in these effects, since these reactive species are scavenged by melatonin [17,43,44]. On the other hand, it is feasible that NMDA receptor overstimulation was involved in the L-2-HG-induced impairment of cell redox since the classical antagonist of these receptors MK-801 prevented lipid oxidative damage and antioxidant defense decrease.

We also observed that L-2-HG increased GPx, GR and GST activities, and inhibited G6PD activity in cerebral cortex. We presume that the increased activities of GPx and GST might have occurred due to the overexpression of these enzymes at gene level in order to compensate the increased formation of lipid peroxides, which is in line with the fact that L-2-HG increases MDA levels, a lipid peroxidation end product. In this particular, it is known that GST also detoxifies 4-hydroxynonenal and isoprostanes that are lipid peroxidation products [17]. Furthermore, increased GR activity also suggests overexpression of this enzyme protein aiming to recycle GSH once the concentrations of this antioxidant are decreased. As regards to the L-2-HG-induced decrease of G6PD activity, we speculate that it occurred due to reactive species attack causing modifications in the enzyme protein structure as previously shown for this and other antioxidant enzymes [45,46].

Since oxidative stress results from an imbalance between the total antioxidant defenses and the reactive species generated in a tissue, our present data strongly indicate that L-2-HG induces oxidative stress *in vivo* in rat cerebral cortex. It must be emphasized that ROS are capable to oxidize various molecules, including lipids, proteins, sugars, and DNA, representing a key event in the pathogenic cascade leading to necrotic and apoptotic cell death [47,48]. Furthermore, oxidative stress is a very deleterious condition especially to the brain due to its high rate of oxidative metabolism coupled to ROS production, lower activity of antioxidant enzymes, and higher peroxidation potential (high content of polyunsaturated fatty acids) [17].

It was also demonstrated in this study that L-2-HG provoked extensive edema and vacuolation in the cerebral cortex of the animals, with less intense effects in the striatum. Although not proven, we assume that these brain abnormalities could be possibly related to the disruption of redox homeostasis elicited by this organic acid [16,49-51].

It is difficult at present to determine the pathophysiological relevance of our data since brain concentrations of L-2-HG in L-2-HGA are still unknown. We cannot rule out the possibility that intracerebral L-2-HG concentrations in the present study were supraphysiological, so that our findings must be taken carefully. However, the concentrations of organic acids accumulating within neural cells in organic acidemias were reported to be usually much higher than those of plasma and cerebrospinal fluid (trapping theory) of patients with various organic acidemias [52]. Furthermore, L-2-HGA is considered a cerebral organic acidemia because L-2-HG is trapped in the CNS [53,54], where at high concentrations it potentially can exert its neurotoxic effects disturbing cellular redox homeostasis.

Conclusion

In conclusion, this is the first report showing that L-2-HG administration to neonatal rats induces *in vivo* lipid and protein oxidative damage and disrupts the antioxidant defenses mainly in the cerebral cortex. These effects were prevented by the potent antioxidant melatonin and the NMDA antagonist MK-801, implying that reactive species generation and overstimulation of these glutamate receptors may underlie the altered cellular redox status. These *in vivo* data allied to previous *in vitro* [14] and *in vivo* [16] experimental animal and humans studies [40,55] strongly indicate that imbalance of redox homeostasis may potentially contribute at least in part to the neurologic alterations found in L-2-HGA. Moreover, it is conceivable that sustained elevated levels of L-2-HG found in the patients may lead to chronic oxidative stress. Another novel and important finding of the present study is that this organic acid provoked histopathological alterations more evident in the cerebral cortex probably due to the induced disruption of redox homeostasis. It may be presumed that our present findings acting synergistically with other intrinsic (severity of mutations) and extrinsic factors may contribute to explain the pathophysiology of the neurologic symptoms and brain abnormalities observed in the affected patients. In case our present *in vivo* results can be confirmed in tissues (blood and cultivated fibroblasts) from individuals affected by L-2HGA, it is therefore tempting to speculate that antioxidants could be supplemented to the affected patients as a potential adjuvant therapy to prevent or attenuate oxidative damage.

Compliance with Ethical Standards

Ethical Approval

The experimental protocol was approved by the Ethics Committee for Animal Research of the UFRGS, Porto Alegre, Brazil, and followed the “National Institutes of Health Guide for the Care and Use of Laboratory Animals” (NIH Publications No. 85–23, revised 2011).

Conflict of Interest

The authors declare that they have no conflict of interest.

References

1. Topcu M, Jobard F, Halliez S, Coskun T, Yalcinkayal C, Gerceker FO, Wanders RJ, Prud'homme JF, Lathrop M, Ozguc M, Fischer J (2004) L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1. *Human molecular genetics* 13 (22):2803-2811. doi:10.1093/hmg/ddh300
2. Barth PG, Hoffmann GF, Jaeken J, Wanders RJ, Duran M, Jansen GA, Jakobs C, Lehnert W, Hanefeld F, Valk J, et al. (1993) L-2-hydroxyglutaric acidaemia: clinical and biochemical findings in 12 patients and preliminary report on L-2-hydroxyacid dehydrogenase. *Journal of inherited metabolic disease* 16 (4):753-761. <https://doi.org/10.1007/BF00711907>
3. Barbot C, Fineza I, Diogo L, Maia M, Melo J, Guimaraes A, Pires MM, Cardoso ML, Vilarinho L (1997) L-2-Hydroxyglutaric aciduria: clinical, biochemical and magnetic resonance imaging in six Portuguese pediatric patients. *Brain & development* 19 (4):268-273. [https://doi.org/10.1016/S0387-7604\(97\)00574-3](https://doi.org/10.1016/S0387-7604(97)00574-3)
4. Topcu M, Aydin OF, Yalcinkaya C, Haliloglu G, Aysun S, Anlar B, Topaloglu H, Turanli G, Yalnizoglu D, Kesimer M, Coskun T (2005) L-2-hydroxyglutaric aciduria: a report of 29 patients. *The Turkish journal of pediatrics* 47 (1):1-7
5. Steenweg ME, Salomons GS, Yapici Z, Uziel G, Scalais E, Zafeiriou DI, Ruiz-Falco ML, Mejaski-Bosnjak V, Augoustides-Savvopoulou P, Wajner M, Walter J, Verhoeven-Duif NM, Struys EA, Jakobs C, van der Knaap MS (2009) L-2-Hydroxyglutaric aciduria: pattern of MR imaging abnormalities in 56 patients. *Radiology* 251 (3):856-865. doi:10.1148/radiol.2513080647
6. Steenweg ME, Jakobs C, Errami A, van Dooren SJ, Adeva Bartolome MT, Aerssens P, Augoustides-Savvopoulou P, Baric I, Baumann M, Bonafe L, Chabrol B, Clarke JT, Clayton P, Coker M, Cooper S, Falik-Zaccai T, Gorman M, Hahn A, Hasanoglu A, King MD, de Klerk HB, Korman SH, Lee C, Meldgaard Lund A, Mejaski-Bosnjak V, Pascual-Castroviejo I, Raadhaksha A, Rootwelt T, Roubertie A, Ruiz-Falco ML, Scalais E, Schimmel U, Seijo-Martinez M, Suri M, Sykut-Cegielska J, Trefz FK, Uziel G, Valayannopoulos V, Vianey-Saban C, Vlaho S, Vodopituz J, Wajner M, Walter J, Walter-Derbort C, Yapici Z, Zafeiriou DI, Spreuwenberg MD, Celli J, den Dunnen JT, van der Knaap MS, Salomons GS (2010) An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. *Human mutation* 31 (4):380-390. doi:10.1002/humu.21197
7. Balaji P, Viswanathan V, Chellathurai A, Panigrahi D (2014) An interesting case of metabolic dystonia: L-2 hydroxyglutaric aciduria. *Annals of Indian Academy of Neurology* 17 (1):97-99. doi:10.4103/0972-2327.128565
8. Wajner M, Goodman SI (2011) Disruption of mitochondrial homeostasis in organic acidurias: insights from human and animal studies. *Journal of bioenergetics and biomembranes* 43 (1):31-38. doi:10.1007/s10863-011-9324-0

9. Yilmaz K (2009) Riboflavin treatment in a case with l-2-hydroxyglutaric aciduria. *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society* 13 (1):57-60. doi:10.1016/j.ejpn.2008.01.003
10. Patay Z, Mills JC, Lobel U, Lambert A, Sablauer A, Ellison DW (2012) Cerebral neoplasms in L-2 hydroxyglutaric aciduria: 3 new cases and meta-analysis of literature data. *AJNR American journal of neuroradiology* 33 (5):940-943. doi:10.3174/ajnr.A2869
11. Marcel C, Mallaret M, Lagha-Boukbiza O, Kremer S, Echaniz-Laguna A, Tranchant C (2012) L-2-hydroxyglutaric aciduria diagnosed in a young adult with progressive cerebellar ataxia and facial dyskinesia. *Revue neurologique* 168 (2):187-191. doi:10.1016/j.neurol.2011.06.002
12. Jovic NJ, Kosac A, Koprivsek K (2014) L-2-Hydroxyglutaric aciduria: a case report. *Srpski arhiv za celokupno lekarstvo* 142 (5-6):337-341. doi: 10.2298/SARH1406337J
13. da Silva CG, Bueno AR, Schuck PF, Leipnitz G, Ribeiro CA, Wannmacher CM, Wyse AT, Wajner M (2003) L-2-hydroxyglutaric acid inhibits mitochondrial creatine kinase activity from cerebellum of developing rats. *International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience* 21 (4):217-224. doi: 10.1016/S0736-5748(03)00035-2
14. Latini A, Scussiato K, Rosa RB, Leipnitz G, Llesuy S, Bello-Klein A, Dutra-Filho CS, Wajner M (2003) Induction of oxidative stress by L-2-hydroxyglutaric acid in rat brain. *Journal of neuroscience research* 74 (1):103-110. doi:10.1002/jnr.10735
15. Junqueira D, Brusque AM, Porciuncula LO, Rotta LN, Ribeiro CA, Frizzo ME, Dutra Filho CS, Wannmacher CM, Wyse AT, Souza DO, Wajner M (2003) Effects of L-2-hydroxyglutaric acid on various parameters of the glutamatergic system in cerebral cortex of rats. *Metabolic brain disease* 18 (3):233-243
16. da Rosa MS, Joao Ribeiro CA, Seminotti B, Teixeira Ribeiro R, Amaral AU, Coelho Dde M, de Oliveira FH, Leipnitz G, Wajner M (2015) In vivo intracerebral administration of L-2-hydroxyglutaric acid provokes oxidative stress and histopathological alterations in striatum and cerebellum of adolescent rats. *Free radical biology & medicine* 83:201-213. doi:10.1016/j.freeradbiomed.2015.02.008
17. Halliwell B GJ (2015) Cellular responses to oxidative stress: adaptation, damage, repair, senescence and death. In: *Free radicals in biology and medicine*. Oxford University Press Inc, Oxford, pp 199-283
18. Olivera-Bravo S, Fernandez A, Sarlabos MN, Rosillo JC, Casanova G, Jimenez M, Barbeito L (2011) Neonatal astrocyte damage is sufficient to trigger progressive striatal degeneration in a rat model of glutaric acidemia-I. *PloS one* 6 (6):e20831. doi:10.1371/journal.pone.0020831
19. Olivera-Bravo S, Isasi E, Fernandez A, Rosillo JC, Jimenez M, Casanova G, Sarlabos MN, Barbeito L (2014) White matter injury induced by perinatal exposure to glutaric acid. *Neurotoxicity research* 25 (4):381-391. doi:10.1007/s12640-013-9445-9

20. Olivier P, Fontaine RH, Loron G, Van Steenwinckel J, Biran V, Massonneau V, Kaindl A, Dalous J, Charriaut-Marlangue C, Aigrot MS, Pansiot J, Verney C, Gressens P, Baud O (2009) Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. *PloS one* 4 (9):e7128. doi:10.1371/journal.pone.0007128
21. Yagi K (1998) Simple procedure for specific assay of lipid hydroperoxides in serum or plasma. *Methods in molecular biology* 108:107-110. doi:10.1385/0-89603-472-0:107
22. Aksenov MY, Markesbery WR (2001) Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. *Neuroscience letters* 302 (2-3):141-145. doi: 10.1016/S0304-3940(01)01636-6
23. Reznick AZ, Packer L (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. *Methods in enzymology* 233:357-363. doi: 10.1016/S0076-6879(94)33041-7
24. Browne RW, Armstrong D (1998) Reduced glutathione and glutathione disulfide. *Methods in molecular biology* 108:347-352. doi:10.1385/0-89603-472-0:347
25. LeBel CP, Ischiropoulos H, Bondy SC (1992) Evaluation of the probe 2',7'-dichlorofluorescein as an indicator of reactive oxygen species formation and oxidative stress. *Chemical research in toxicology* 5 (2):227-231. doi: 10.1021/tx00026a012
26. Navarro-Gonzalvez JA, Garcia-Benayas C, Arenas J (1998) Semiautomated measurement of nitrate in biological fluids. *Clinical chemistry* 44 (3):679-681
27. Wendel A (1981) Glutathione peroxidase. *Methods in enzymology* 77:325-333
28. Carlberg I, Mannervik B (1985) Glutathione reductase. *Methods in enzymology* 113:484-490
29. Mannervik B, Guthenberg C (1981) Glutathione transferase (human placenta). *Methods in enzymology* 77:231-235
30. Leong SF, Clark JB (1984) Regional development of glutamate dehydrogenase in the rat brain. *Journal of neurochemistry* 43 (1):106-111
31. Aebi H (1984) Catalase in vitro. *Methods in enzymology* 105:121-126
32. Marklund SL (1985) Product of extracellular-superoxide dismutase catalysis. *FEBS letters* 184 (2):237-239
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. *The Journal of biological chemistry* 193 (1):265-275
34. Levine RL, Williams JA, Stadtman ER, Shacter E (1994) Carbonyl assays for determination of oxidatively modified proteins. *Methods in enzymology* 233:346-357. doi: 10.1016/S0076-6879(94)33040-9
35. Requejo R, Chouchani ET, Hurd TR, Menger KE, Hampton MB, Murphy MP (2010) Measuring mitochondrial protein thiol redox state. *Methods in enzymology* 474:123-147. doi:10.1016/S0076-6879(10)74008-8

36. Moroni I, Bugiani M, D'Incerti L, Maccagnano C, Rimoldi M, Bissola L, Pollo B, Finocchiaro G, Uziel G (2004) L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? *Neurology* 62 (10):1882-1884. doi:10.1212/01.WNL.0000125335.21381.87
37. Haliloglu G, Jobard F, Oguz KK, Anlar B, Akalan N, Coskun T, Sass JO, Fischer J, Topcu M (2008) L-2-hydroxyglutaric aciduria and brain tumors in children with mutations in the L2HGDH gene: neuroimaging findings. *Neuropediatrics* 39 (2):119-122. doi:10.1055/s-2008-1081217
38. Aghili M, Zahedi F, Rafiee E (2009) Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. *Journal of neuro-oncology* 91 (2):233-236. doi:10.1007/s11060-008-9706-2
39. Rzem R, Van Schaftingen E, Veiga-da-Cunha M (2006) The gene mutated in l-2-hydroxyglutaric aciduria encodes l-2-hydroxyglutarate dehydrogenase. *Biochimie* 88 (1):113-116. doi:10.1016/j.biochi.2005.06.005
40. Rodrigues DGB, de Moura Coelho D, Sitta A, Jacques CED, Hauschild T, Manfredini V, Bakkali A, Struys EA, Jakobs C, Wajner M, Vargas CR (2017) Experimental evidence of oxidative stress in patients with l-2-hydroxyglutaric aciduria and that l-carnitine attenuates in vitro DNA damage caused by d-2-hydroxyglutaric and l-2-hydroxyglutaric acids. *Toxicology in vitro : an international journal published in association with BIBRA* 42:47-53. doi:10.1016/j.tiv.2017.04.006
41. Anghileri E, Bertolino N, Salsano E, Antelmi L, Carpinelli P, Castellotti B, Zucca I, Gellera C, Bisogno R, Caccia C, Cuccarini V (2016) In-vivo brain H1-MR-Spectroscopy identification and quantification of 2-hydroxyglutarate in L-2-Hydroxyglutaric aciduria. *Brain research* 1648 (Pt A):506-511. doi:10.1016/j.brainres.2016.08.013
42. Fourati H, Ellouze E, Ahmadi M, Chaari D, Kamoun F, Hsairi I, Triki C, Mnif Z (2016) MRI features in 17 patients with l2 hydroxyglutaric aciduria. *European journal of radiology open* 3:245-250. doi:10.1016/j.ejro.2016.09.001
43. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA (2006) Melatonin as antioxidant, geroprotector and anticarcinogen. *Biochimica et biophysica acta* 1757 (5-6):573-589. doi:10.1016/j.bbabbio.2006.03.012
44. Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC (2013) The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. *Mini reviews in medicinal chemistry* 13 (3):373-384. doi: 10.2174/1389557511313030006
45. Grings M, Moura AP, Parmeggiani B, Pletsch JT, Cardoso GMF, August PM, Matte C, Wyse ATS, Wajner M, Leipnitz G (2017) Bezafibrate prevents mitochondrial dysfunction, antioxidant system disturbance, glial reactivity and neuronal damage induced by sulfite administration in striatum of rats: Implications for a possible therapeutic strategy for sulfite oxidase deficiency. *Biochimica et biophysica acta* 1863 (9):2135-2148. doi:10.1016/j.bbadis.2017.05.019
46. Seminotti B, Amaral AU, Ribeiro RT, Rodrigues MDN, Colin-Gonzalez AL, Leipnitz G, Santamaria A, Wajner M (2016) Oxidative Stress, Disrupted Energy Metabolism, and Altered

Signaling Pathways in Glutaryl-CoA Dehydrogenase Knockout Mice: Potential Implications of Quinolinic Acid Toxicity in the Neuropathology of Glutaric Acidemia Type I. *Molecular neurobiology* 53 (9):6459-6475. doi:10.1007/s12035-015-9548-9

47. Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. *Free radical biology & medicine* 48 (6):749-762. doi:10.1016/j.freeradbiomed.2009.12.022

48. Niizuma K, Endo H, Chan PH (2009) Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. *Journal of neurochemistry* 109 Suppl 1:133-138. doi:10.1111/j.1471-4159.2009.05897.x

49. Cubells JF, Rayport S, Rajendran G, Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 14 (4):2260-2271

50. Wilt SG, Dugger NV, Hitt ND, Hoffman PM (2000) Evidence for oxidative damage in a murine leukemia virus-induced neurodegeneration. *Journal of neuroscience research* 62 (3):440-450. doi:10.1002/1097-4547(20001101)62:3<440::AID-JNR14>3.0.CO;2-M

51. Saxena G, Bharti S, Kamat PK, Sharma S, Nath C (2010) Melatonin alleviates memory deficits and neuronal degeneration induced by intracerebroventricular administration of streptozotocin in rats. *Pharmacology, biochemistry, and behavior* 94 (3):397-403. doi:10.1016/j.pbb.2009.09.022

52. Hoffmann GF, Meier-Augenstein W, Stockler S, Surtees R, Rating D, Nyhan WL (1993) Physiology and pathophysiology of organic acids in cerebrospinal fluid. *Journal of inherited metabolic disease* 16 (4):648-669

53. Sauer SW, Okun JG, Fricker G, Mahringer A, Muller I, Crnic LR, Muhlhausen C, Hoffmann GF, Horster F, Goodman SI, Harding CO, Koeller DM, Kolker S (2006) Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. *Journal of neurochemistry* 97 (3):899-910. doi:10.1111/j.1471-4159.2006.03813.x

54. Sauer SW, Opp S, Mahringer A, Kaminski MM, Thiel C, Okun JG, Fricker G, Morath MA, Kolker S (2010) Glutaric aciduria type I and methylmalonic aciduria: simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the blood-brain barrier and the choroid plexus. *Biochimica et biophysica acta* 1802 (6):552-560. doi:10.1016/j.bbadis.2010.03.003

55. Jellouli NK, Hadj Salem I, Ellouz E, Kamoun Z, kamoun F, tlili A, Kaabachi N, Triki C, Fakhfakh F, Tunisian Network on Mental Retardation s (2014) Founder effect confirmation of c.241A>G mutation in the L2HGDH gene and characterization of oxidative stress parameters in six Tunisian families with L-2-hydroxyglutaric aciduria. *Journal of human genetics* 59 (4):216-222. doi:10.1038/jhg.2014.4

Legend to figures

Fig. 1 Effect of intracerebral administration of L-2-hydroxyglutaric acid (L-2-HG; 0.750 $\mu\text{mol/g}$) on malondialdehyde (MDA) levels (A), carbonyl formation (B) and sulfhydryl content (C) in cerebral cortex of neonatal rats. Data are represented as mean \pm SD for four to six independent experiments (animals) performed in triplicate and are expressed as nmol / mg protein. * P <0.5, ** P <0.01, compared to control (Student's t test for unpaired samples).

Fig. 2 Effect of intracerebral administration of L-2-hydroxyglutaric acid (L-2-HG; 0.750 $\mu\text{mol/g}$) on concentrations of GSH in cerebral cortex of neonatal rats. Data are represented as mean \pm SD for four to six independent experiments (animals) performed in triplicate and are expressed as nmol / mg protein. *** P <0.001, compared to control (Student's t test for unpaired samples)

Fig. 3 Effect of intracerebral administration of L-2-hydroxyglutaric acid (L-2-HG; 0.750 $\mu\text{mol/g}$) on DCFH oxidation (A) in cerebral cortex and nitrate and nitrite concentrations (B) in forebrain of neonatal rats. Data are represented as mean \pm SD for four to six independent experiments (animals) performed in triplicate and are expressed as μmol / mg protein. * P <0.5, compared to control (Student's t test for unpaired samples)

Fig. 4 Effect of melatonin (MEL; 20 mg/Kg) and MK-801 (0,25mg/Kg) on L-2-hydroxyglutaric acid (L-2-HG 0.750 $\mu\text{mol/g}$)-induced increase of MDA (A) and decrease of GSH concentrations (B) in cerebral cortex of neonatal rats. Data are represented as mean \pm SD for four to six independent experiments (animals) performed in triplicate and are expressed as nmol / mg protein. * P <0.05, compared to control; # P <0.05, ## P <0.01, ### P <0.001, compared to L-2-HG (Student's t test for unpaired samples)

Fig. 5 Effect of intracerebral administration of L-2-hydroxyglutaric acid (L-2-HG; 0.750 $\mu\text{mol/g}$) on the activities of glucose-6-phosphate dehydrogenase (G6PDH) (A), glutathione peroxidase (GPx) (B), glutathione reductase (GR) (C), glutathione S-transferase (GST) (D), catalase (CAT) (E) and superoxide dismutase (SOD) in cerebral cortex of neonatal rats. Data are represented as mean \pm SD for four to six independent experiments (animals) performed in triplicate and are expressed as U / mg protein. * P <0.05, ** P <0.01 compared to control (Student's t test for unpaired samples)

Fig. 6 Effect of intracerebral administration of L-2-hydroxyglutaric acid (L-2-HG; 0.750 $\mu\text{mol/g}$) on sulfhydryl content (A) and the activities of glutathione peroxidase (GPx) (B), glucose-6-phosphate dehydrogenase (G6PDH) (C) and superoxide dismutase (SOD) (D) in striatum of neonatal rats. * P <0.05, ** P <0.01, *** P <0.001, compared to control (Student's t test for unpaired samples)

Fig. 7 Light microscopy images showing hematoxylin and eosin (HE) staining of cerebral cortex from PBS (control, A and C) and L-2-hydroxyglutaric acid (L-2-HG)-injected neonatal rats (B and D). Animals were sacrificed 24 hours after L-2-HG intracerebroventricular administration. Representative images were obtained from four rats per group. HE staining with magnification of 100x and 400x. Arrows in panel D indicate vacuolation.

Fig. 8 Light microscopy images showing hematoxylin and eosin (HE) staining of striatum from PBS (control, A and C) and L-2-hydroxyglutaric acid (L-2-HG)-injected neonatal rats (B and D). Animals

were sacrificed 24 hours after intracerebroventricular administration. Representative images were obtained from four rats per group. HE staining with magnification of 100x and 400x. Arrows in panel D indicate vacuolation.

ANEXO I – FIGURAS

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7








FIGURE 8

PBS

L-2-HG




ANEXO II – NORMAS PARA PUBLICAÇÃO

Periódico “Molecular Neurobiology”

Neuroscience

Home > Biomedical Sciences > Neuroscience

SUBDISCIPLINES JOURNALS BOOKS SERIES TEXTBOOKS REFERENCE WORKS



Molecular Neurobiology

Editor-in-Chief: Nicolas G. **Bazan**

ISSN: 0893-7648 (print version)

ISSN: 1559-1182 (electronic version)

Journal no. 12035



\$99.00 [Personal Rate e-only for the Americas](#)

[Get Subscription](#)

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 10 issue(-s) per annual subscription

Automatic annual renewal

More information: >> [FAQs](#) // >> [Policy](#)

[ABOUT THIS JOURNAL](#) [EDITORIAL BOARD](#) [ETHICS & DISCLOSURES](#) [INSTRUCTIONS FOR AUTHORS](#)

Instructions for Authors

MANUSCRIPT SUBMISSION

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink "Submit online" on the right and upload all of your manuscript files following the instructions given on the screen.

ORCID ID

This publication requires that the corresponding author provides his/her ORCID ID before proceeding with submission.

For more information about this journal's ORCID policy, please visit the [ORCID FAQ](#)

TITLE PAGE

Title Page

The title page should include:

- ⌘ The name(s) of the author(s)
- ⌘ A concise and informative title
- ⌘ The affiliation(s) and address(es) of the author(s)
- ⌘ The e-mail address, and telephone number(s) of the corresponding author
- ⌘ If available, the 16-digit ORCID of the author(s)

Abstract

Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.

Keywords

Please provide 4 to 6 keywords which can be used for indexing purposes.

TEXT

Text Formatting

Manuscripts should be submitted in Word.

- ⌘ Use a normal, plain font (e.g., 10-point Times Roman) for text.
- ⌘ Use italics for emphasis.
- ⌘ Use the automatic page numbering function to number the pages.
- ⌘ Do not use field functions.
- ⌘ Use tab stops or other commands for indents, not the space bar.
- ⌘ Use the table function, not spreadsheets, to make tables.
- ⌘ Use the equation editor or MathType for equations.
- ⌘ Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).

Manuscripts with mathematical content can also be submitted in LaTeX.

LaTeX macro package (zip, 182 kB)

Headings

Please use no more than three levels of displayed headings.

Abbreviations

Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.

Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data).

Footnotes to the title or the authors of the article are not given reference symbols.

Always use footnotes instead of endnotes.

Acknowledgments

Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.

REFERENCES

Citation

Reference citations in the text should be identified by numbers in square brackets. Some examples:

1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].

Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.

The entries in the list should be numbered consecutively.

⌘ Journal article

Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. *Eur J Appl Physiol* 105:731-738.
<https://doi.org/10.1007/s00421-008-0955-8>

Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted:

Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. *N Engl J Med* 965:325–329

⌘ Article by DOI

Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. *J Mol Med*. <https://doi.org/10.1007/s001090000086>

⌘ Book

South J, Blass B (2001) *The future of modern genomics*. Blackwell, London

⌘ Book chapter

Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) *The rise of modern genomics*, 3rd edn. Wiley, New York, pp 230-257

⌘ Online document

Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. <http://physicsweb.org/articles/news/11/6/16/1>. Accessed 26 June 2007

⌘ Dissertation

Trent JW (1975) *Experimental acute renal failure*. Dissertation, University of California

Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see

ISSN.org LTWA

If you are unsure, please use the full journal title.

For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.

EndNote style (zip, 2 kB)

Authors preparing their manuscript in LaTeX can use the bibtex file spbasic.bst which is included in Springer's LaTeX macro package.

TABLES


- ⌘ All tables are to be numbered using Arabic numerals.
- ⌘ Tables should always be cited in text in consecutive numerical order.
- ⌘ For each table, please supply a table caption (title) explaining the components of the table.
- ⌘ Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
- ⌘ Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.

ARTWORK AND ILLUSTRATIONS GUIDELINES

Electronic Figure Submission

- ⌘ Supply all figures electronically.
- ⌘ Indicate what graphics program was used to create the artwork.
- ⌘ For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.
- ⌘ Vector graphics containing fonts must have the fonts embedded in the files.
- ⌘ Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.

Line Art



- ⌘ Definition: Black and white graphic with no shading.


- ⌘ Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
- ⌘ All lines should be at least 0.1 mm (0.3 pt) wide.
- ⌘ Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
- ⌘ Vector graphics containing fonts must have the fonts embedded in the files.

Halftone Art


Definition: Photographs, drawings, or paintings with fine shading, etc.

If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.

Halftones should have a minimum resolution of 300 dpi.



Combination Art



Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.

Combination artwork should have a minimum resolution of 600 dpi.

Color Art

Color art is free of charge for online publication.

If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another

when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.

If the figures will be printed in black and white, do not refer to color in the captions. Color illustrations should be submitted as RGB (8 bits per channel).

Figure Lettering

- ⌘ To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
- ⌘ Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
- ⌘ Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
- ⌘ Avoid effects such as shading, outline letters, etc.
- ⌘ Do not include titles or captions within your illustrations.

Figure Numbering

All figures are to be numbered using Arabic numerals.

Figures should always be cited in text in consecutive numerical order.

Figure parts should be denoted by lowercase letters (a, b, c, etc.).

If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.

Figure Captions

- ⌘ Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
- ⌘ Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
- ⌘ No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
- ⌘ Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
- ⌘ Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Figure Placement and Size

Figures should be submitted separately from the text, if possible.

When preparing your figures, size figures to fit in the column width.

For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.

For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 198 mm.

Permissions

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Accessibility

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that

All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)

Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)

Any figure lettering has a contrast ratio of at least 4.5:1

ELECTRONIC SUPPLEMENTARY MATERIAL

Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form.

Before submitting research datasets as electronic supplementary material, authors should read the journal's Research data policy. We encourage research data to be archived in data repositories wherever possible.

Submission

Supply all supplementary material in standard file formats.

Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.

To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.

Audio, Video, and Animations

Aspect ratio: 16:9 or 4:3

Maximum file size: 25 GB

Minimum video duration: 1 sec

Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp

Text and Presentations

Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.

A collection of figures may also be combined in a PDF file.

Spreadsheets

Spreadsheets should be submitted as .csv or .xlsx files (MS Excel).

Specialized Formats

Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files

It is possible to collect multiple files in a .zip or .gz file.

Numbering

If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.

Refer to the supplementary files as "Online Resource", e.g., "... as shown in the animation (Online Resource 3)", "... additional data are given in Online Resource 4". Name the files consecutively, e.g. "ESM_3.mpg", "ESM_4.pdf".

Captions

For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files

Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.

Accessibility

In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that

The manuscript contains a descriptive caption for each supplementary material
Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

ENGLISH LANGUAGE EDITING

For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English you should consider:

Asking a colleague who is a native English speaker to review your manuscript for clarity.

Visiting the English language tutorial which covers the common mistakes when writing in English.

Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review.

Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their first submission to either of these services, simply follow the links below.

English language tutorial

Nature Research Editing Service

American Journal Experts

Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted.

If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.

.

为便于编辑和评审专家准确评估您稿件中陈述的研究工作，您需要确保您的英语语言质量足以令人理解。如果您需要英文写作方面的帮助，您可以考虑：

- 请一位以英语为母语的同事审核您的稿件是否表意清晰。
- 查看一些有关英语写作中常见语言错误的教程。
- 使用专业语言编辑服务，编辑人员会对英语进行润色，以确保您的意思表达清晰，并识别需要您复核的问题。我们的附属机构 Nature Research Editing Service 和合作伙伴 American Journal Experts 即可提供此类服务。

教程

Nature Research Editing Service

American Journal Experts

请注意，使用语言编辑服务并非在期刊上发表文章的必要条件，同时也并不意味或保证文章将被选中进行同行评议或被接受。

如果您的稿件被接受，在发表之前，我们的文字编辑会检查您的文稿拼写是否规范以及文体是否正式。

エディターと査読者があなたの論文を正しく評価するには、使用されている英語の質が十分に高いことが必要とされます。英語での論文執筆に際してサポートが必要な場合には、次のオプションがあります：

- ・英語を母国語とする同僚に、原稿で使用されている英語が明確であるかをチェックしてもらう。
- ・英語で執筆する際によくある間違いに関する英語のチュートリアルを参照する。
- ・プロの英文校正サービスを利用する。校正者が原稿の意味を明確にしたり、問題点を指摘し、英語の質を向上させます。Nature Research Editing Service とAmerican Journal Experts の2つは弊社と提携しているサービスです。Springer の著者は、いずれのサービスも初めて利用する際には10%の割引を受けることができます。以下のリンクを参照ください。

英語のチュートリアル

Nature Research Editing Service

American Journal Experts

英文校正サービスの利用は、投稿先のジャーナルに掲載されるための条件ではないこと、また論文審査や受理を保証するものではないことに留意してください。

原稿が受理されると、出版前に弊社のコピーエディターがスペルと体裁のチェックを行います。

영어 원고의 경우, 에디터 및 리뷰어들이 귀하의 원고에 실린 결과물을 정확하게 평가할 수 있도록, 그들이 충분히 이해할 수 있을 만한 수준으로 작성되어야 합니다. 만약 영작문과 관련하여 도움을 받기를 원하신다면 다음의 사항들을 고려하여 주십시오:

- ・ 귀하의 원고의 표현을 명확히 해줄 영어 원어민 동료를 찾아서 리뷰를 의뢰합니다.
- ・ 영어 튜토리얼 페이지에 방문하여 영어로 글을 쓸 때 자주하는 실수들을 확인합니다.
- ・ 리뷰에 대비하여, 원고의 의미를 명확하게 해주고 리뷰에서 요구하는 문제점들을 식별해서 영문 수준을 향상시켜주는 전문 영문 교정 서비스를 이용합니다. Nature Research Editing Service 와 American Journal Experts에서 저희와 협약을 통해 서비스를 제공하고 있습니다. Springer 저자들이 본 교정 서비스를 첫 논문 투고를 위해 사용하시는 경우 10%의 할인이 적용되며, 아래의 링크를 통하여 확인이 가능합니다.

영어 튜토리얼 페이지

Nature Research Editing Service

American Journal Experts

영문 교정 서비스는 게재를 위한 요구사항은 아니며, 해당 서비스의 이용이 피어 리뷰에 논문이 선택되거나 게재가 수락되는 것을 의미하거나 보장하지 않습니다.

원고가 수락될 경우, 출판 전 저희측 편집자에 의해 원고의 철자 및 문체를 검수하는 과정을 거치게 됩니다.

ETHICAL RESPONSIBILITIES OF AUTHORS

This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct.

Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation can be achieved by following the rules of good scientific practice, which include:

- ⌘ The manuscript has not been submitted to more than one journal for simultaneous consideration.
- ⌘ The manuscript has not been published previously (partly or in full), unless the new work concerns an expansion of previous work (please provide transparency on the re-use of material to avoid the hint of text-recycling (“self-plagiarism”).
- ⌘ A single study is not split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (e.g. “salami-publishing”).
- ⌘ No data have been fabricated or manipulated (including images) to support your conclusions
- ⌘ No data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks are used for verbatim copying of material, and permissions are secured for material that is copyrighted.

Important note: the journal may use software to screen for plagiarism.

- ⌘ Consent to submit has been received explicitly from all co-authors, as well as from the responsible authorities - tacitly or explicitly - at the institute/organization where the work has been carried out, **before** the work is submitted.
- ⌘ Authors whose names appear on the submission have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results.
- ⌘ Authors are strongly advised to ensure the correct author group, corresponding author, and order of authors at submission. Changes of authorship or in the order of authors are **not** accepted **after** acceptance of a manuscript.
- ⌘ Adding and/or deleting authors and/or changing the order of authors **at revision stage** may be justifiably warranted. A letter must accompany the revised manuscript to explain the reason for the change(s) and the contribution role(s) of the added and/or deleted author(s). Further documentation may be required to support your request.
- ⌘ Requests for addition or removal of authors as a result of authorship disputes after acceptance are honored after formal notification by the institute or independent body and/or when there is agreement between all authors.
- ⌘ Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential proprietary data is excluded.

If there is a suspicion of misconduct, the journal will carry out an investigation following the COPE guidelines. If, after investigation, the allegation seems to raise valid concerns, the accused author will be contacted and given an opportunity to address the issue. If misconduct has been established beyond reasonable doubt, this may result in the Editor-in-Chief’s implementation of the following measures, including, but not limited to:

If the article is still under consideration, it may be rejected and returned to the author. If the article has already been published online, depending on the nature and severity of the infraction, either an erratum will be placed with the article or in severe cases complete retraction of the article will occur. The reason must be given in the

published erratum or retraction note. Please note that retraction means that the paper is **maintained on the platform**, watermarked "retracted" and explanation for the retraction is provided in a note linked to the watermarked article.

The author's institution may be informed.

COMPLIANCE WITH ETHICAL STANDARDS

To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.

Authors should include the following statements (if applicable) in a separate section entitled "Compliance with Ethical Standards" when submitting a paper:

Disclosure of potential conflicts of interest
Research involving Human Participants and/or Animals
Informed consent

Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. single or double blind peer review) as well as per journal subject discipline. Before submitting your article check the instructions following this section carefully.

The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication.

The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. Examples of potential conflicts of interests **that are directly or indirectly related to the research** may include but are not limited to the following:

- ⌘ Research grants from funding agencies (please give the research funder and the grant number)
- ⌘ Honoraria for speaking at symposia
- ⌘ Financial support for attending symposia
- ⌘ Financial support for educational programs
- ⌘ Employment or consultation
- ⌘ Support from a project sponsor
- ⌘ Position on advisory board or board of directors or other type of management relationships
- ⌘ Multiple affiliations
- ⌘ Financial relationships, for example equity ownership or investment interest
- ⌘ Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
- ⌘ Holdings of spouse and/or children that may have financial interest in the work

In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are not

limited to personal relationships or competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that may influence your research.

The corresponding author collects the conflict of interest disclosure forms from all authors. In author collaborations where formal agreements for representation allow it, it is sufficient for the corresponding author to sign the disclosure form on behalf of all authors. Examples of forms can be found

here:

The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s).

See below examples of disclosures:

Funding: This study was funded by X (grant number X).

Conflict of Interest: Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.

If no conflict exists, the authors should state:

Conflict of Interest: The authors declare that they have no conflict of interest.

AFTER ACCEPTANCE

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer's web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice, offprints, or printing of figures in color.

Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.

Copyright transfer

Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.

Creative Commons Attribution-NonCommercial 4.0 International License

Offprints

Offprints can be ordered by the corresponding author.

Color illustrations

Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs.

Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.

After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

OPEN CHOICE

In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer's online platform SpringerLink.

[Open Choice](#)

[Copyright and license term – CC BY](#)

Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

[Find more about the license agreement](#)

READ THIS JOURNAL ON SPRINGERLINK

[Online First Articles](#)

[All Volumes & Issues](#)

FOR AUTHORS AND EDITORS

2016 Impact Factor

6.190

[Aims and Scope](#)

[Submit Online](#)

[Open Choice - Your Way to Open Access](#)

[Instructions for Authors](#)

[Author Academy: Training for Authors](#)

SERVICES FOR THE JOURNAL

[Contacts](#)

[Download Product Flyer](#)

[Shipping Dates](#)

[Order Back Issues](#)

ALERTS FOR THIS JOURNAL

Get the table of contents of every new issue published in [Molecular Neurobiology](#).

Your E-Mail Address

SUBMIT

Please send me information on new Springer publications in [Neurosciences](#).

